Pseudophakic cystoid maculopathy: a study of 50 cases.
The incidence of clinical cystoid macular edema (CME) in routine cataract surgery is about 2%. Clinically significant pseudophakic maculopathy has a higher incidence and is more severe. Fifty cases of CME following intracapsular cataract extraction and intraocular lens implantation in a series of 821 consecutive cases were reviewed. The overall incidence of pseudophakic cystoid macular edema (PCME) was 6.1%. Several clinical observations were made: (1) Young patients, or those under 65, had a much higher incidence of PCME, approaching 20%; (2) chronic inflammation is responsible for pseudophakic cystoid maculopathy; (3) systemic steroid therapy of CME in the pseudophakic patient was beneficial in 80% of the cases, with a response within ten days; and (4) pseudophakic cystoid maculopathy is almost always recurrent and frequently requires maintenance suppression with daily steroid drops after recovery. Forty-four percent of these patients did not recover better than 20/40 visual acuity, suggesting that CME in the pseudophakic patient is not a benign, self-limited disease.
D000085:Acetates / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D002387:Cataract Extraction; D004487:Edema / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D005128:Eye Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D005260:Female; D006801:Humans; D007910:Lenses, Intraocular; D008266:Macula Lutea; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D011239:Prednisolone / Q000031:analogs & derivatives / Q000627:therapeutic use; D011379:Prognosis
D000085:Acetates; C009935:prednisolone acetate; D011239:Prednisolone